Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

Inclusion Criteria: * ECOG performance status 0 or 1 * Adult patients ≥ 18 years and ≤ 75 years of age * Histologic or cytologic proven adenocarcinoma of the pancreas (histologic confirmation of diagnosis is preferred) * Confirmation by independent multidisciplinary expert review of borderline resectable status, according to NCCN-Clinical Practice Guidelines in Oncology "pancreatic adenocarcinoma", version 1.2015. * Adequate hematologic function, as follows: * absolute neutrophil count (ANC) ≥ \> 2000/mm3 * platelet count ≥ 100 000/mm3 * haemoglobin ≥ 10 g/dL * Adequate renal, hepatic and bone marrow function, defined as: * Calculated creatinine clearance ≥ 50 mL/min according to MDRD formula * Serum total bilirubin ≤ 1.5 times the institutional upper limit of normal. Patients with a biliary short metal stent due to cancer obstruction may be included provided that high-quality imaging is performed before stenting and bilirubin level after stent insertion decreased to ≤ 20 mg/L (≤ 34 µmol/l), and there is no cholangitis. * Male and female subjects who agree to use highly effective methods of birth control (e.g., condoms, combined oral contraceptives, some intrauterine devices \[IUDs\], sexual abstinence, or sterilized partner) * for male subject: during the treatment and for up to 6 months after the last dose of oxaliplatin or up to 3 months after the last dose of irinotcan. * for female subject: during the treatment and for up to 4 months after the last dose of oxa…